



This is the published version 
 
Lofgren, Hans 2013, Novartis vs. the government of India: patents and public 

























Copyright: 2013, East Asia Forum 
 
East Asia Forum
Economics, Politics and Public Policy in East Asia
and the Pacific
http://www.eastasiaforum.org
Novartis vs. the government of India: patents and public
health 
26th April, 2013
Author: Hans Lofgren, Deakin University
In early April, India’s Supreme Court rejected an application by the Swiss multinational
pharmaceutical company Novartis for a patent on a modified version of the leukemia medication
imatinib mesylate.
[1]
Naturally, the outcome of the case affects the affordability of the drug. But the core issue was
the right of the Indian government to take account of public health in designing intellectual
property rights (IPR) legislation.
In India, Novartis charges about US$26,000 per patent per year for the drug, marketed as
Glivec (Gleevec in the United States). But generic versions produced by local companies are
available for less than US$2,500. Novartis’s price excludes all patients except the extremely
rich, although the company supplies Glivec for free to some patients. The Indian government
and civil society groups [2] see this situation as health policy being held hostage to corporate
charity. And to them that is unacceptable.
The Novartis case confirms the right of India’s parliament to implement public health
safeguards available under the Agreement of Trade-Related Intellectual Property Rights
(TRIPS). These include the definition of patentability criteria, the central issue in this case. Such
‘flexibilities’ mostly revolve around the conditions for market entry of alternative generic brands
— the term generic drug refers to a copy of an original product whose patent has expired.
In India, all drugs were generics before 2005 because there were no product patents for
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pharmaceuticals. India became fully TRIPS compliant in 2005 through the introduction of
pharmaceutical patents, with legislation that included safeguards to protect public health. In
particular, section 3(d) of India’s Patent Act was included to prevent the extension of patent
protection through minor product modifications, unless a ‘significant enhancement of efficacy’
can be demonstrated.
Novartis took legal action against the Indian government to challenge the constitutionality of
section 3(d). When this was rejected, the company sought to have imatinib mesylate recognised
as patentable. But it did not even purport to demonstrate enhanced efficacy. Novartis aimed to
put a stop to generic competition in the imatinib mesylate market. And it was also attempting to
prevent the export of locally produced, more affordable brands to other developing countries. In
its judgment, the court determined that imatinib mesylate is not patentable as it ‘fails the test of
section 3(d)’.
The Supreme Court judgment has given rise to an enormous amount of global commentary.
Public health advocates and patients greeted the outcome with great relief. Médecins Sans
Frontières [3], Joseph Stiglitz [4] and various media outlets [5] hailed the decision. They see it as a
good precedent for drug affordability in developing countries in general. In contrast, Novartis
and fellow corporate giants such as Pfizer [6] reacted with dismay. For example, Novartis is
reported [7] to have ‘threatened to stop supplying India with new medicines’. This overwrought
reaction points to a crisis in their traditional business model. The industry is being reshaped due
to issues such as steadily falling R&D productivity and political mobilisations for access to
medicines for all.
The Novartis case is important because it highlights that it’s no longer acceptable to the global
public that hundreds of millions of people are denied access to life-saving drugs because of
monopoly pricing. And the case shows that governments in developing countries with some
economic and political clout, such as India’s, are prepared to fight the big pharmaceutical
companies. But Novartis and its peers will not abandon the Indian market in reaction against
measures to make drugs more affordable. India is too important an economy and continues to 
offer plentiful opportunities [8] for international pharmaceutical companies. And Indian firms are
large-scale suppliers of low-cost generics to Western markets as well. These firms have an
impact on global industry dynamics, and many collaborate with the international companies.
India has changed a lot in regards to its pharmaceuticals market. Between independence in
1947 and the 1970s it was highly dependent on imports of expensive medicines. But between
1970 and 2005 India abolished product patents on medicines. The Indian government also put
in place industrial policy measures and public sector research institutions to collaborate with
local producers. The result was a strong and vibrant Indian generic industry. The entry of
generics lowers prices and widens access to medicines. And it is much more effective in
achieving these outcomes than philanthropy or the model of tiered or differential pricing
strategies preferred by multinational companies. The patenting of trivial modifications, known as
‘evergreening’, is one of a host of ‘life-cycle management’ techniques employed in response to
generics competition.
Nevertheless, the Indian government will continue to face challenges from international
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pharmaceutical companies seeking to stifle generic competition. Bayer recently sought to
overturn [9] a precedent-setting compulsory license on another cancer drug awarded to
Hyderabad-based Natco Pharma in 2012. An appeals court in March this year rejected Bayer’s
application. The Novartis and Bayer cases suggest that India is well placed to defend and
extend pharmaceutical and IPR policies aimed at balancing economic development with public
health.
Hans Lofgren is Associate Professor in the School of Humanities and Social Sciences [10],
Deakin University.






[2] civil society groups: http://www.cpaaindia.org/
[3] Médecins Sans Frontières: 
http://www.msf.org/msf/articles/2013/04/indian-supreme-court-delivers-verdict-in-novartis
-case.cfm.htm
[4] Joseph Stiglitz: 
http://www.project-syndicate.org/print/the-impact-of-the-indian-supreme-court-s-patent-d
ecision-by-joseph-e--stiglitz-and-arjun-jayadev
[5] various media outlets: 
http://www.huffingtonpost.com/matthew-kavanagh/drug-patents_b_3007729.html
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[6] such as Pfizer: 
http://online.wsj.com/article/SB10001424127887323296504578395672582230106.html
[7] Novartis is reported:
http://www.guardian.co.uk/world/2013/apr/01/novartis-denied-cancer-drug-patent-india
[8] offer plentiful opportunities:
http://www.pwc.in/en_IN/in/assets/pdfs/pharma/pharma-summit-report-31-10-12.pdf
[9] Bayer recently sought to overturn: 
http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/arti
cle4475762.ece
[10] School of Humanities and Social Sciences: 
http://www.deakin.edu.au/arts-ed/shss/staff-directory2.php?username=hvml
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